Trial Profile
A Phase 1 Study of LY2606368 in Japanese Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Nov 2018
Price :
$35
*
At a glance
- Drugs Prexasertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 01 Oct 2018 Results published in the Cancer Science
- 19 May 2017 Status changed from active, no longer recruiting to completed.
- 08 Mar 2017 Status changed from recruiting to active, no longer recruiting.